UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2008-01, Vol.26 (1), p.90-95

2008

Volltextzugriff (PDF)

Exposure Levels Associated With Na131I Thyroid Cancer Patients: Correlation With Initial Activity and Clinical Physical Parameters

Health physics (1958), 2014-08, Vol.107 (2), p.S163-S165

2014

Volltextzugriff (PDF)

Modification of a motel-type room to accommodate patients receiving radioiodine therapy: reduction of environmental exposure

Health physics (1958), 2012-08, Vol.103 (2 Suppl 2), p.S131-S135

2012

Volltextzugriff (PDF)

Abstract PO4-20-10: Value of 16α-18F-fluoro-17β-fluoroestradiol PET imaging in ER-positive breast cancer: a case report

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO4-20-10-PO4-20-10

2024

Volltextzugriff (PDF)

Exposure levels associated with Na(131)I thyroid cancer patients: correlation with initial activity and clinical physical parameters

Health physics (1958), 2014-08, Vol.107 (2 Suppl 2), p.S163

2014

Volltextzugriff (PDF)

Pilot study of HER2 targeted 64Cu-DOTA-tagged PET imaging in gastric cancer patients

Nuclear medicine communications, 2023-12, Vol.44 (12), p.1151-1155

2023

Volltextzugriff (PDF)

Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13070-e13070

2022

Volltextzugriff (PDF)

A Radionuclide Therapy Treatment Planning and Dose Estimation System

The Journal of nuclear medicine (1978), 1999-07, Vol.40 (7), p.1151-1153

1999

Volltextzugriff (PDF)

Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies

Cancer biotherapy & radiopharmaceuticals, 2020-02, Vol.35 (1), p.10-15

2020

Volltextzugriff (PDF)

Pilot study of HER2 targeted 64 Cu-DOTA-tagged PET imaging in gastric cancer patients

Nuclear medicine communications, 2023-12, Vol.44 (12), p.1151

2023

Volltextzugriff (PDF)

Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer

Clinical cancer research, 2004-08, Vol.10 (15), p.5014-5021

2004

Volltextzugriff (PDF)

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

Blood advances, 2020-10, Vol.4 (20), p.5194-5202

2020

Volltextzugriff (PDF)

The two types of correction of absorbed dose estimates for internal emitters

Cancer, 2002-02, Vol.94 (S4), p.1231-1234

2002

Volltextzugriff (PDF)

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Blood, 2015-12, Vol.126 (23), p.3179-3179

2015

Volltextzugriff (PDF)

Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer

Clinical cancer research, 1999-10, Vol.5 (10), p.3224s

1999

Volltextzugriff (PDF)

Abstract 6788: hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6788-6788

2023

Volltextzugriff (PDF)

Abstract OT3-03-01: Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT3-03-01-OT3-03-01

2023

Volltextzugriff (PDF)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

Blood advances, 2021-12, Vol.5 (23), p.5300-5311

2021

Volltextzugriff (PDF)

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Blood, 2010-11, Vol.116 (21), p.32-32

2010

Volltextzugriff (PDF)

A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer

Clinical cancer research, 2003-12, Vol.9 (16), p.5842-5852

2003

Volltextzugriff (PDF)

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma

Blood, 2009-11, Vol.114 (22), p.3423-3423

2009

Volltextzugriff (PDF)

90.y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Blood, 2009-11, Vol.114 (22), p.3357-3357

2009

Volltextzugriff (PDF)

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL)

Blood, 2009-11, Vol.114 (22), p.2323-2323

2009

Volltextzugriff (PDF)

A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

Cancer biotherapy & radiopharmaceuticals, 2010-08, Vol.25 (4), p.387-394

2010

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

Humans
(24)
Science & Technology
(22)
Life Sciences & Biomedicine
(20)
Female
(15)
Male
(12)
Middle Aged
(12)
Radioimmunotherapy
(11)
Adult
(10)
Aged
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Radiology, Nuclear Medicine & Medical Imaging
(9)
Yttrium Radioisotopes - Therapeutic Use
(9)
Antibodies, Monoclonal - Therapeutic Use
(8)
Carcinoembryonic Antigen - Immunology
(8)
Animals
(6)
Mice
(6)
Oncology
(6)
Antineoplastic Agents
(5)
Hematology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Exposure Levels Associated With Na131I Thyroid Cancer Patients: Correlation With Initial Activity and Clinical Physical Parameters

Modification of a motel-type room to accommodate patients receiving radioiodine therapy: reduction of environmental exposure

Abstract PO4-20-10: Value of 16α-18F-fluoro-17β-fluoroestradiol PET imaging in ER-positive breast cancer: a case report

Exposure levels associated with Na(131)I thyroid cancer patients: correlation with initial activity and clinical physical parameters

Pilot study of HER2 targeted 64Cu-DOTA-tagged PET imaging in gastric cancer patients

Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer

A Radionuclide Therapy Treatment Planning and Dose Estimation System

Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies

Pilot study of HER2 targeted 64 Cu-DOTA-tagged PET imaging in gastric cancer patients

Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

The two types of correction of absorbed dose estimates for internal emitters

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer

Abstract 6788: hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer

Abstract OT3-03-01: Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma

90.y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL)

A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

Suchergebnisse filtern